Company Analysis
Sign in

Invivyd, Inc. (IVVD)

Nasdaq: IVVD · Biological Products, (No Diagnostic Substances) · New Haven, CT · filing with the SEC since 2020
Full chart Alerts Compare
Grade5.2
◀ Past 5.3● Present 5.3▶ Future 5.1
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

3 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Invivyd, Inc.’s names, not what it holds today.

Patents granted
3
3 utility, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
6
1 of them in 2025
Names they are printed under
3
a former name, its own name
By yearGrantedApplications published
'21'22'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology3
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
Adagio Therapeutics, Inc. a former name
named as the applicant on its applications, in US
0 granted
4 published
Adagio Therapeutics, Inc. a former name
US, as the owner printed on each patent
3 granted
0 published
Invivyd, Inc. its own name
named as the applicant on its applications, in US
0 granted
2 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Aug 16, 202211,414,479Compounds specific to coronavirus S protein and uses thereofBiotechnologyAdagio Therapeutics, Inc.
Jan 11, 202211,220,536Compounds specific to coronavirus S protein and uses thereofBiotechnologyAdagio Therapeutics, Inc.
Dec 7, 202111,192,940Compounds specific to coronavirus S protein and uses thereofBiotechnologyAdagio Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jul 10, 20252025/0223339SARS-COV2 ANTIBODIES AND USES THEREOFBiotechnologyInvivyd, Inc.
Dec 26, 20242024/0425567PHARMACEUTICAL FORMULATIONS COMPRISING ANTI-CORONAVIRUS S PROTEIN ANTIBODIES AND USES THEREOFBiotechnologyInvivyd, Inc.
May 19, 20222022/0153815COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOFBiotechnologyAdagio Therapeutics, Inc.
Jan 13, 20222022/0010002COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOFBiotechnologyAdagio Therapeutics, Inc. · patent 11,220,536 granted from it
Dec 16, 20212021/0388067COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOFBiotechnologyAdagio Therapeutics, Inc. · patent 11,414,479 granted from it
Oct 21, 20212021/0324048COMPOUNDS SPECIFIC TO CORONAVIRUS S PROTEIN AND USES THEREOFBiotechnologyAdagio Therapeutics, Inc. · patent 11,192,940 granted from it
What it applied for, 2024 to 2025: Biotechnology 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton IVVD · research, not advice